Expanding Options in Obesity Management: Strategies to Individualize Treatment

Endocrinology
Curriculum:
Expanding Options in Obesity Management: Strategies to Individualize Treatment
Credits:
1.25 AMA PRA Category 1 Credit(s)™
Launch Date:
June 30, 2014
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Physicians and other healthcare professionals who treat obesity.

Relevant Terms:

Obesity

Louis J. Aronne, MD, FACP, FTOS

Louis J. Aronne, MD, FACP, FTOS
Program Chair
Clinical Professor of Medicine
Weill Cornell Medical College
Director, Comprehensive Weight Control Program
New York-Presbyterian Hospital
New York, New York

Dr Aronne is clinical professor of medicine at Weill Cornell Medical College and adjunct associate clinical professor of medicine at Columbia University College of Physicians and Surgeons in New York, New York. He is also director of the Comprehensive Weight Control Program at New York-Presbyterian Hospital. Dr Aronne received a medical degree from The Johns Hopkins University School of Medicine in Baltimore, Maryland. He completed an internship and residency in medicine at Albert Einstein College of Medicine and the Bronx Municipal Hospital Center in New York. He then completed a fellowship in medicine at The Henry J. Kaiser Family Foundation. Dr Aronne is recognized internationally as an obesity specialist. His book, The Skinny on Losing Weight Without Being Hungry, is a New York Times bestseller. He contributes regularly to health publications and has authored numerous articles and book chapters on obesity. He is a founding board member and director of the American Board of Obesity Medicine.

Ken Fujioka, MD

Ken Fujioka, MD
Director, Center for Weight Management
Director, Nutrition and Metabolic
Research Center
Scripps Clinic
San Diego, California

Dr Fujioka is director of both the Center for Weight Management and the Nutrition and Metabolic Research Center at Scripps Clinic in San Diego, California. He received a medical degree from the University of Hawaii, John A. Burns School of Medicine, where he also completed an internship and residency in internal medicine. He then completed a fellowship in diabetes and clinical nutrition at the University of Southern California Medical Center in Los Angeles. Dr Fujioka has authored or coauthored more than 40 scientific papers and has completed more than 75 clinical trials in obesity and other related diseases including diabetes, hypercholesterolemia, and hypertension. He is a reviewer for The Journal of the American Medical Association and Diabetes Care.

Robert F. Kushner, MD, FACP, FTOS

Robert F. Kushner, MD, FACP, FTOS
Professor of Medicine
Northwestern University Feinberg School of Medicine
Director, Center for Lifestyle Medicine
Northwestern Memorial Hospital
Chicago, Illinois

Dr Kushner is professor of medicine at Northwestern University Feinberg School of Medicine, clinical director of the Northwestern Comprehensive Center on Obesity, and medical director of the Center for Lifestyle Medicine in Chicago, Illinois. Dr Kushner received a medical degree from the University of Illinois. He completed an internship and residency in internal medicine at Northwestern Memorial Hospital in Chicago and a fellowship in clinical nutrition at The University of Chicago Hospitals. Dr Kushner currently serves as chair of the American Board of Obesity Medicine. He is on the editorial board for the Journal of the Academy of Nutrition and Dietetics and has contributed to and reviewed a number of publications. He is an internationally recognized expert on the care of overweight and obese patients, and he has written a number of books on the subject of health and obesity.

ACCME Course Director: Caroline M. Apovian, MD, FACP, FACN, FTOS

Caroline M. Apovian, MD, FACP, FACN, FTOS
ACCME Course Director
Professor of Medicine
Boston University School of Medicine
Director, Center for Nutrition and Weight Management
Boston Medical Center
Boston, Massachusetts

1. Discuss new findings in the pathobiology of obesity and the impact of new treatments on weight regulation
2. Describe risks:benefits of weight loss medications in treating overweight, obesity, and comorbid conditions
3. Evaluate risk stratification schemes for patients who are overweight or obese
4. Lead a multidisciplinary team to optimize treatment success for patients who are overweight or obese

JOINTLY PROVIDED BY 



ACCREDITATION INFORMATION
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Continuing Education Alliance. Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 
 
Boston University School of Medicine designates this Enduring material for a maximum of 1.25  AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
ACKNOWLEDGEMENT
This activity is supported by an educational grant from Eisai Inc.

FACULTY DISCLOSURE
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any discussion of unapproved use of pharmaceuticals and devices is being discussed.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration.
 
Dr Apovian: advisory board: Arena Pharmaceuticals, Inc., EnteroMedics Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Nutrisystem, Zafgen; advisory board/research grants: Amylin Pharmaceuticals, LLC, Orexigen Therapeutics, Inc., sanofi-aventis; research grants: Aspire Bariatrics, LLC, The Dr. Robert C. and Veronica Atkins Foundation, Eli Lilly and Company, GI Dynamics, MetaProteomics, Pfizer Inc.
 
Dr Aronne: advisory board/consultant: Arena Pharmaceuticals, Inc., Eisai Inc., Ethicon Endo-Surgery, Inc., GlaxoSmithKline, Orexigen Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Vivus Inc., Zafgen; advisory board/consultant/research grants: Amylin Pharmaceuticals, LLC, Novo Nordisk A/S; board of directors/ownership interest:Myos Corporation; ownership interest: Cardiometabolic Support Network, LLC, Zafgen; research grants: Aspire Bariatrics, LLC, GI Dynamics, High Point Pharmaceuticals, LLC, Medical University of South Carolina.
 
Dr Fujioka: consultant: Isis Pharmaceuticals, Inc., Zafgen; consultant/research grants: Novo Nordisk A/S, Orexigen Therapeutics, Inc.; consultant/research grants/speakers bureau: Eisai Inc., NPS Pharmaceuticals, Inc.; research grants: EnteroMedics Inc., Shire, Weight Watchers International, Inc.; speakers bureau: Abbott Laboratories, Merck & Co., Inc.
 
Dr Kushner: consultant: Novo Nordisk A/S, Retrofit, Inc., Vivus Inc.; research grants: Aspire Bariatrics, LLC, Weight Watchers International, Inc.

The Planning Committee for this activity included Mike Burk of Boston University School of Medicine; and Ruth Cohen and Christie Avraamides, PhD of Continuing Education Alliance. The members of the Planning Committee have no significant relationships to disclose.

The following agents may be discussed off-label: bupropion, GLP-1 inhibitors, metformin, and SGLT-2 inhibitors.

DISCLAIMER
THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTHCARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.
 
HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.25 AMA PRA category 1 credits™. Statement of credit will be available to print from your user history page.
 
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
  • Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score with a 70% or higher on the post-test to receive credit for this activity.
  • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
  • Statement of credit will be available to print from your user history page.
CONTACT INFORMATION
For CME questions, please contact: cme@bu.edu. The BUSM CME course code for this program is E.OBESEWEEKCEA13. For information on the Boston University School of Medicine Privacy Policy, please visit: www.bu.edu/cme/policies/privacy_policy.html.
 
 
COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 5.0+ for Mac OSX 10.5 and above

For video playback, install the latest version of Flash or Quicktime.